A different bispecific, humanized IgG1 antibody which is underneath investigation is zenocutuzumab (MCLA-128), which functions through two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells through ADCC. MCLA-128 features by using a ‘dock and block’ mechanism whereby 1 arm of your antibody binds HER2 domain https://www.directivepublications.org/journal-of-clinical-breast-cancer/